*Patients with difficult-to-treat migraine were episodic and chronic migraine patients who had documented failure to 2-4 classes of migraine preventive medications2
Hi, I'm AJOVY® Bot.
Click here to ask questions about AJOVY®
To access this section of the AJOVY® website you need to be a member of the healthcare profession because the materials included in this area of our website are specifically prepared for that audience only.
Please click on the appropriate button below to confirm that you are a healthcare professional.
This Web site may contain links or references to other Web sites maintained by third parties over whom Teva, Inc. ("Teva") has no control. Links are provided as a convenient resource to our visitors. We carefully choose Web sites which we believe are useful based on our high standards. However, Web sites can change. Teva cannot guarantee the standards of every Web site link or be responsible for the content of non-Teva Web sites. Inclusion of any third-party link does not imply an endorsement or recommendation by Teva.
Similarly, this Web site may be accessed from third-party links over which Teva has no control. Teva makes no warranties or representations of any kind as to the accuracy, currency, or completeness of any information contained in such Web sites and shall have no liability for any damages or injuries of any kind arising from such content or information.
*Patients with difficult-to-treat migraine were episodic and chronic migraine patients who had documented failure to 2-4 classes of migraine preventive medications2
